These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28680915)

  • 21. An enrichment strategy for clinical trials in SPMS.
    Koch MW; Metz L; Cutter G
    Mult Scler; 2021 Oct; 27(12):1884-1893. PubMed ID: 33404355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
    Jiang X; Shen C; Teunissen CE; Wessels M; Zetterberg H; Giovannoni G; Singh CM; Caba B; Elliott C; Fisher E; de Moor C; Belachew S; Gafson AR
    Mult Scler; 2023 Aug; 29(9):1070-1079. PubMed ID: 37317870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Goldman MD; LaRocca NG; Rudick RA; Hudson LD; Chin PS; Francis GS; Jacobs A; Kapoor R; Matthews PM; Mowry EM; Balcer LJ; Panzara M; Phillips G; Uitdehaag BMJ; Cohen JA;
    Neurology; 2019 Nov; 93(21):e1921-e1931. PubMed ID: 31641014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of multi-function swing suspension training on upper and lower extremities function and quality of life in multiple sclerosis women with different disability status.
    Far SS; Amiri B; Sahebozamani M; Ebrahimi HA; Zemková E
    Mult Scler Relat Disord; 2023 Dec; 80():105113. PubMed ID: 37924713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients.
    Stellmann JP; Vettorazzi E; Poettgen J; Heesen C
    J Neurol Sci; 2014 Nov; 346(1-2):99-106. PubMed ID: 25156343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential of Timed 25-Foot Walk Values in Predicting Maximum Walking Distance in Persons with Multiple Sclerosis.
    Alshamrani F; Berger W; Alnajashi H; Payne MWC; Morrow SA
    Int J MS Care; 2020; 22(5):215-218. PubMed ID: 33177957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of different doses of gadolinium contrast agent on clinical outcomes in MS.
    Ackermans N; Taylor C; Tam R; Carruthers R; Kolind S; Kang H; Freedman MS; Li DK; Traboulsee AL
    Mult Scler J Exp Transl Clin; 2019; 5(1):2055217318823796. PubMed ID: 30800415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
    Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM
    Mult Scler; 2010 Jul; 16(7):862-7. PubMed ID: 20488826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis.
    Brenton JN; Koshiya H; Woolbright E; Goldman MD
    Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319846141. PubMed ID: 31065380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis.
    Koch MW; Repovic P; Mostert J; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G
    Eur J Neurol; 2023 Sep; 30(9):2761-2768. PubMed ID: 37306560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain reserve and physical disability in secondary progressive multiple sclerosis.
    John N; Li Y; De Angelis F; Stutters J; Prados Carrasco F; Eshaghi A; Doshi A; Calvi A; Williams T; Plantone D; Phan T; Barkhof F; Chataway J; ; Ourselin S; Braisher M; Beyene T; Bassan V; Zapata A; Chandran S; Connick P; Lyle D; Cameron J; Mollison D; Colville S; Dhillon B; Ross M; Cranswick G; Walker A; Smith L; Giovannoni G; Gnanapavan S; Nicholas R; Rashid W; Aram J; Ford H; Pavitt SH; Overell J; Young C; Arndt H; Duddy M; Guadagno J; Evangelou N; Craner M; Palace J; Hobart J; Sharrack B; Paling D; Hawkins C; Kalra S; McLean B; Stallard N; Bastow R
    BMJ Neurol Open; 2024; 6(2):e000670. PubMed ID: 39262426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis.
    van 't Hullenaar CAA; Coerver E; Kalkers NF; van Kempen Z; Koch M; Uitdehaag BMJ; Killestein J; Strijbis EMM
    Mult Scler Relat Disord; 2021 Oct; 55():103165. PubMed ID: 34404022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    Baeva ME; Tottenham I; Koch M; Camara-Lemarroy C
    J Neuroimmunol; 2024 Feb; 387():578268. PubMed ID: 38157653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EDSS variability before randomization may limit treatment discovery in primary progressive MS.
    Zhang J; Waubant E; Cutter G; Wolinsky JS; Glanzman R
    Mult Scler; 2013 May; 19(6):775-81. PubMed ID: 23027880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.
    Healy BC; Glanz BI; Swallow E; Signorovitch J; Hagan K; Silva D; Pelletier C; Chitnis T; Weiner H
    Mult Scler J Exp Transl Clin; 2021; 7(2):2055217321999070. PubMed ID: 33953937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study.
    Hardmeier M; Schindler C; Kuhle J; Fuhr P
    Front Neurol; 2020; 11():735. PubMed ID: 32793104
    [No Abstract]   [Full Text] [Related]  

  • 38. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
    Dalla Costa G; Nos C; Zabalza A; Buron M; Magyari M; Sellebjerg F; Guerrero AI; Roselli L; La Porta ML; Martinis M; Bailon R; Kontaxis S; Laporta E; Garcia E; Pokorny FB; Schuller BW; Folarin A; Stewart C; Leocani L; Vairavan S; Cummins N; Dobson R; Hotopf M; Narayan V; Montalban X; Sorensen PS; Comi G
    Mult Scler; 2024 Jan; 30(1):103-112. PubMed ID: 38084497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative sensory and motor measures detect change overtime and correlate with walking speed in individuals with multiple sclerosis.
    Zackowski KM; Wang JI; McGready J; Calabresi PA; Newsome SD
    Mult Scler Relat Disord; 2015 Jan; 4(1):67-74. PubMed ID: 25692092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis.
    Jakimovski D; Kavak KS; Zakalik K; Bromley L; Ozel O; Qutab N; Eckert SP; Kolb C; Weinstock-Guttman B
    Mult Scler J Exp Transl Clin; 2022; 8(2):20552173221099186. PubMed ID: 35571975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.